Today, $CRSP and @VertexPharma announced that the EMA has granted PRIME designation to CTX001, for the treatment of severe #SickleCellDisease. Learn more here: https://t.co/OWTfid4kvI
— CRISPR Therapeutics (@CRISPRTX) September 22, 2020
Tomorrow is #WorldSickleCellDay and we’ll be shining a light on #SickleCellDisease (SCD) with NY State Sickle Cell Disease Partnership and @VertexPharma. To learn more about SCD and the community it impacts, register for the virtual event here: https://t.co/vAmhA0Y2ah pic.twitter.com/4Z7genyoaN
— CRISPR Therapeutics (@CRISPRTX) June 18, 2020
#Breaking: Today, $CRSP and @VertexPharma announced new clinical data and progress for CTX001™ in severe hemoglobinopathies at the #EHA25Virtual Congress. Learn more here: https://t.co/R3FpEp0JCz pic.twitter.com/2hoUqTo7Vu
— CRISPR Therapeutics (@CRISPRTX) June 12, 2020
#BREAKING: $CRSP, in collaboration with @VertexPharma, announced the presentation of new data for CTX001 at the upcoming #EHA25Virtual meeting. Learn more here: https://t.co/60fjRoxE90 pic.twitter.com/b7gUoylIj8
— CRISPR Therapeutics (@CRISPRTX) May 14, 2020
$CRSP and @VertexPharma announce early positive safety and efficacy data from the first two patients treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 for severe hemoglobinopathies. Learn more here: https://t.co/voTH4xtnK1
— CRISPR Therapeutics (@CRISPRTX) November 19, 2019
Today we’re excited to #shinethelightonsicklecell with our partners at @VertexPharma. Learn more about Sickle Cell Disease here: https://t.co/BgrJRFE88E #WorldSickleCellAwarenessDay pic.twitter.com/zRVm6O2RaA
— CRISPR Therapeutics (@CRISPRTX) June 19, 2019
On this #WorldSickleCellDay, we’re standing behind the people living with #sicklecell disease and their caregivers. We’re proud to work with @VertexPharma to advance new treatment options for those living with this devastating disease. #WSCD2019
— CRISPR Therapeutics (@CRISPRTX) June 19, 2019
$CRSP and @VertexPharma announce that the U.S. FDA granted Fast Track Designation for CRISPR gene-edited therapy CTX001 for the treatment of #betathalassemia. Learn more here: https://t.co/6Lu4tKDHgs
— CRISPR Therapeutics (@CRISPRTX) April 16, 2019
$CRSP and Vertex announce progress in clinical development programs for the investigational CRISPR/Cas9 gene-editing therapy CTX001: https://t.co/9WMMmoNkVV pic.twitter.com/2DFWan0Swg
— CRISPR Therapeutics (@CRISPRTX) February 25, 2019
$CRSP and @VertexPharma announce that the U.S. FDA granted Fast Track Designation for CTX001, a CRISPR gene-edited therapy for the treatment of #sicklecell disease. Learn more here: https://t.co/s9nqaGyijZ
— CRISPR Therapeutics (@CRISPRTX) January 4, 2019
$CRSP and @VertexPharma announce @FDA lifts clinical hold on investigational new drug application. Read the press release here: https://t.co/McELZLvrzH
— CRISPR Therapeutics (@CRISPRTX) October 10, 2018
Today @VertexPharma opted in to co-develop and co-commercialize CTX001, an investigational gene-editing treatment. $CRSP is excited to partner with $VRTX to develop a potentially transformative therapy for sickle cell disease and beta thalassemia https://t.co/3asYeMoy2T
— CRISPR Therapeutics (@CRISPRTX) December 12, 2017
$CRSP awarded @CureFA_org grant to study gene-edited treatments for Friedreich’s Ataxia with @UofAlabama Birmingham https://t.co/u8r18UywEL
— CRISPR Therapeutics (@CRISPRTX) October 13, 2017
Here’s what we know about all the planned CRISPR trials so far: https://t.co/2SaUgjOmLI
— Emily Mullin (@emilylmullin) December 18, 2017
Last week, Crispr Therapeutics announced it has asked regulators in Europe for permission to trial a cure for the disease beta thalassemia https://t.co/3bydECY5H1
— WIRED (@WIRED) December 12, 2017
CRISPR used to "chew up" toxic RNA and almost completely reverse symptoms in of myotonic dystrophy in mice. Many other severe neuromuscular diseases, such as Huntington’s and ALS, are also caused by similar RNA buildup @UCSDMedSchool @yeo_lab https://t.co/nKYGp9jNNq
— CRISPR News (@CRISPR_News) September 15, 2020
A bit of #COVID19 news this morning, but #science marches on. Who'll win the #NobelPrize in medicine & chem next week? Comment on my story or tweet whether you like picks @RockefellerUniv, @harvardme, @RutgersU etc. h/t @JSheltzer @webofscience https://t.co/sgUGbjNPhu
— sharon begley (@sxbegle) October 2, 2020
Worth attending! Sponsored by @GENbio and @WomenScienceRFS https://t.co/sFs9XGGiYC
— Dr. Joanne Kamens (@JKamens) October 1, 2020
#Breaking U.S. FDA approves expanded indication for our first #cysticfibrosis medicine. Learn more: https://t.co/583hGhAjxO pic.twitter.com/a9iZ9T1P6W
— Vertex (@VertexPharma) September 25, 2020
Vertex announces #CFResearch data being presented at #ECFS2020 and #NACFC2020 for our #cysticfibrosis medicines. Learn more: https://t.co/TMa6XP229p pic.twitter.com/tPIxRrqecd
— Vertex (@VertexPharma) September 24, 2020
We are looking forward to joining the #ECFS2020 Digital Congress. Learn more about this year’s #ECFSgoesdigital meeting: https://t.co/uKLyN6l9v7 pic.twitter.com/cJVXCeiDT0
— Vertex (@VertexPharma) September 24, 2020
Vertex Pharmaceuticals and @CRISPRTX Therapeutics announce Priority Medicines (PRIME) designation granted by the European Medicines Agency (EMA) to our investigational medicine for the treatment of sickle cell disease. Learn more: https://t.co/hXGq992ykn pic.twitter.com/CrWsLRc6sG
— Vertex (@VertexPharma) September 22, 2020
Vertex announces positive Phase 3 data for one of our #cysticfibrosis medicines. Learn more: https://t.co/swKPYTtWWJ pic.twitter.com/z1uJ7XW8mv
— Vertex (@VertexPharma) September 10, 2020
The Vertex Foundation announced a €1 million donation to the @RMHC_Ireland at the new children’s hospital to support building their new accommodation, which will provide housing to families while their children receive medical treatment: https://t.co/OdzxyBontV pic.twitter.com/BTi604dIKq
— Vertex (@VertexPharma) September 10, 2020
.@VertexPharma received marketing authorization in Europe for our fourth #cysticfibrosis medicine for eligible people living with #CF ages 12 years and older in #Europe. Learn more: https://t.co/iPiS3Q81Wg pic.twitter.com/4PXIELzYO9
— Vertex (@VertexPharma) August 21, 2020
Vertex Reports Second-Quarter 2020 Financial Results. Read the press release here: https://t.co/pdJXIU8Xxn pic.twitter.com/0nQjf2aviQ
— Vertex (@VertexPharma) July 30, 2020
Vertex Announces Positive Phase 3 data for one of our #cysticfibrosis medicines. Learn more: https://t.co/lfl3qlVFES pic.twitter.com/6VY60e4kO8
— Vertex (@VertexPharma) July 20, 2020
.@VertexPharma receives CHMP positive opinion for our fourth #cysticfibrosis medicine for eligible people living with #CF ages 12 and older in #Europe. Learn more: https://t.co/gnPBu1Hm3T pic.twitter.com/UkKuKaBUtN
— Vertex (@VertexPharma) June 26, 2020
@VertexPharma and @CRISPRTX highlight new clinical data and progress for investigational CTX001 programs in severe sickle cell disease and beta thalassemia at the 25th Annual European Hematology Association Congress. https://t.co/HeShYUpi3I #EHA25Virtual #EHA25 #EHA2020 pic.twitter.com/h2D3wtFE9M
— Vertex (@VertexPharma) June 12, 2020
.@VertexPharma announces European commission approval for one of our cystic fibrosis medicines for eligible children and adolescents with #CF between the ages of 6 months and 18 years with a R117H mutation in the CFTR gene. Learn more: https://t.co/t8a46D4nYz pic.twitter.com/TnV5TADTQ7
— Vertex (@VertexPharma) June 11, 2020
Vertex Pharmaceuticals and @CRISPRTX are excited to join the upcoming virtual EHA Congress to present new data on our investigational programs in severe sickle cell disease and transfusion-dependent beta-thalassemia. https://t.co/h6yH3VJ2WT pic.twitter.com/JtC8Bd0gfp
— Vertex (@VertexPharma) May 18, 2020
Partnering with @FrontlineFoods and local #Boston restaurants, the Vertex Foundation has made a donation to ensure that hospital staff on the front lines at @BrighamWomens and @MassGeneralNews receive a total of 10,000 nutritious meals. Learn more: https://t.co/Hcwu14eoIN pic.twitter.com/f7t4Eru1mF
— Vertex (@VertexPharma) May 12, 2020
#Breaking: In collaboration with @CRISPRTX, we announced FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CTX001 under clinical investigation for severe sickle cell disease and transfusion-dependent beta thalassemia: https://t.co/l6XNM6P0xR pic.twitter.com/9OyPaqbF5V
— Vertex (@VertexPharma) May 11, 2020
.@VertexPharma receives European CHMP positive opinion for one of our #cysticfibrosis medicines for eligible people living with #CF ages 6 months and older. Learn more: https://t.co/EpPVtFvaaq pic.twitter.com/vs2FJgiPjX
— Vertex (@VertexPharma) May 1, 2020
@VertexPharma reports first-quarter 2020 financial results. Learn more: https://t.co/vbinydDZVJ pic.twitter.com/E5nhRD7ylE
— Vertex (@VertexPharma) April 29, 2020
.@VertexPharma and Affinia Therapeutics establish multi-year research collaboration to discover and develop transformative genetic therapies. Learn more: https://t.co/vK3a6nZYCV
— Vertex (@VertexPharma) April 27, 2020
.@VertexPharma announces #innovative reimbursement agreement in Switzerland for #cysticfibrosis medicines for eligible patients with #CF. Learn more: https://t.co/2l7ntfFSR6 pic.twitter.com/blpn0FV02Q
— Vertex (@VertexPharma) April 21, 2020
Vertex confirms supply chain continuity and business outlook for approved Cystic Fibrosis medicines and provides an initial update on development programs: https://t.co/glMLVijtgH pic.twitter.com/lTSlmq4l8K
— Vertex (@VertexPharma) March 27, 2020
.@VertexPharma announces availability of a #cysticfibrosis medicine in New Zealand. Learn more and read the full press release here: https://t.co/LH6jfCwZzU pic.twitter.com/KTykaEsBzk
— Vertex (@VertexPharma) February 26, 2020
Vertex announces European Commission approval of an expanded indication for one of our #cysticfibrosis medicines. Learn more: https://t.co/NP8AOUDC7V pic.twitter.com/yORKrm0756
— Vertex (@VertexPharma) December 10, 2019
.@VertexPharma announces an agreement with French authorities for national reimbursement of a #cysticfibrosis medicine. Read the full press release here: https://t.co/XIzjoWr3Z6
— Vertex (@VertexPharma) November 20, 2019
.@CRISPRTX and @VertexPharma announce early positive data from first two patients treated with their investigational CRISPR/Cas9 gene editing therapy for sickle cell disease and beta thalassemia. https://t.co/ggzcBm4ld9 pic.twitter.com/ILOcOiSd20
— Vertex (@VertexPharma) November 19, 2019
.@VertexPharma confirms Wales offer accepted for access to all licensed #cysticfibrosis medicines: https://t.co/4VoiuNPlaj pic.twitter.com/8R0i6tVcVJ
— Vertex (@VertexPharma) November 13, 2019
.@VertexPharma confirms Northern Ireland offer accepted for #cysticfibrosis medicines. Read the full press release here: https://t.co/TfnRfcaHSR
— Vertex (@VertexPharma) November 12, 2019
The data being presented at #NACFC reflect our continued commitment to research in #CF. Check out the new publications in @NEJM and @TheLancet to learn more about the results. https://t.co/g8ot8l5OTa
— Vertex (@VertexPharma) October 31, 2019
Vertex Reports Third-Quarter 2019 Financial Results https://t.co/QOH5HVA1NJ pic.twitter.com/oEaX5clEE0
— Vertex (@VertexPharma) October 30, 2019
Vertex announces agreement with NHS England for access to licensed #cysticfibrosis medicines. Learn more: https://t.co/KxMHZG6nKg pic.twitter.com/M3TschCPIm
— Vertex (@VertexPharma) October 24, 2019
#Breaking U.S. #FDA approves @VertexPharma #cysticfibrosis treatment. Learn more: https://t.co/xw8GfrsbMX pic.twitter.com/YoKYTBxm61
— Vertex (@VertexPharma) October 21, 2019
.@VertexPharma is delighted to announce a reimbursement agreement in Spain. Learn more and read the full press release here: https://t.co/jIgzPYPoVq
— Vertex (@VertexPharma) October 21, 2019
Vertex announces reimbursement of #cysticfibrosis medicines in Australia. Learn more and read the full press release here: https://t.co/eI8fU38tKx
— Vertex (@VertexPharma) October 19, 2019
.@VertexPharma receives positive opinion from European CHMP to treat eligible infants with #CF as early as six months of age. Read the full press release here: https://t.co/mnCUDXzztw
— Vertex (@VertexPharma) October 18, 2019
.@VertexPharma and @Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics. Read the full press release: https://t.co/lcscpmVRzq
— Vertex (@VertexPharma) September 30, 2019
.@VertexPharma is delighted to announce a reimbursement agreement has been signed with the Scottish Government, effective immediately. Read the full press release here: https://t.co/BhQCtNSPm9
— Vertex (@VertexPharma) September 12, 2019
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes https://t.co/oLNv4RjVm7 pic.twitter.com/o0inXUN6lu
— Vertex (@VertexPharma) September 3, 2019
#Breaking U.S. FDA Accepts New Drug Application for Triple Combination Regimen in #cysticfibrosis #CF Learn more: https://t.co/wWnLAjMdPx pic.twitter.com/fezAhbkeVA
— Vertex (@VertexPharma) August 20, 2019
#Breaking New Drug Application Submitted to the U.S. FDA for Triple Combination Regimen in #cysticfibrosis Learn more: https://t.co/LYUBpBtmY8 pic.twitter.com/M3xeVZ5cTw
— Vertex (@VertexPharma) July 22, 2019
The Vertex Foundation is continuing to monitor the #COVID19 response efforts and donate to organizations around the world to provide access to essential #healthcare and #healthsupplies such as testing and #PPE to support the communities hit hardest. https://t.co/QT0hS2Hgce
— Vertex (@VertexPharma) April 7, 2020
Today, after eight incredible years as #CEO, Dr. Jeffrey Leiden will transition to the role of Executive Chairman. We are grateful for all of his contributions to @VertexPharma and excited to welcome Dr. Reshma Kewalramani as our next President and CEO. https://t.co/g40tV5w2uL pic.twitter.com/pR9hpO2ClO
— Vertex (@VertexPharma) April 1, 2020
Vertex Confirms Supply Chain Continuity and 2020 Business Outlook. Read the press release here: https://t.co/eGIRS1PlT5 pic.twitter.com/hfsR1z1CvA
— Vertex (@VertexPharma) March 9, 2020
.@VertexPharma reports full year and fourth quarter 2019 financial results. Learn more: https://t.co/BsxbaUj3Ev
— Vertex (@VertexPharma) January 30, 2020
.@VertexPharma to present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020. Learn more: https://t.co/ckNcGagz1t
— Vertex (@VertexPharma) January 8, 2020
So exciting to be recognized by the Boston Business Journal as the top most charitable company in the ‘life sciences’ category in Massachusetts for 2018! Helping make the places we work and live stronger is part of who we are at Vertex. https://t.co/VtzpmGgxp9
— Vertex (@VertexPharma) September 9, 2019
Today, we stand with the 100+ #nonprofit organizations to back the Pandemic Response & Opportunity Through National Service Act to expand @AmeriCorps to 750k positions over three years. Follow #Stand4Service to learn more and to join in. https://t.co/7rFxKRq9gI
— Vertex (@VertexPharma) May 8, 2020
The Vertex Foundation announced a donation to Food Banks Canada to support its #COVID19 response efforts: https://t.co/BzqrRyYDGI
— Vertex (@VertexPharma) April 23, 2020
The safety of our communities is our top priority. The Vertex Foundation is providing support to the organizations around the world who are working on-the-ground to provide the most vulnerable populations with food, care and education. Learn more: https://t.co/QT0hS2Hgce #COVID19
— Vertex (@VertexPharma) April 7, 2020
.@VertexPharma is delighted to announce a reimbursement agreement in Spain. Learn more and read the full press release here: https://t.co/jIgzPYPoVq
— Vertex (@VertexPharma) October 21, 2019
.@VertexPharma appoints Carmen Bozic, M.D., as new Chief Medical Officer and Nia Tatsis, Ph.D., as new Chief Regulatory Officer. Read the full press release here: https://t.co/qBgxbnhCu8
— Vertex (@VertexPharma) October 1, 2019
Vertex announces Dr. Jeffrey Leiden to transition to role of Executive Chairman, effective April 1, 2020 and Dr. Reshma Kewalramani appointed as new Chief Executive Officer. Read the press release here: https://t.co/ydSUaKSgVz
— Vertex (@VertexPharma) July 25, 2019
Congratulations to @VertexPharma in San Diego for their @SANDAG @iCommuteSD Diamond Award and for maintaining their Platinum Tier status! Vertex is a model for encouraging employees to take transit and walk/bike/rideshare to work! pic.twitter.com/gUPsCwYRMe
— Biocom (@BiocomCA) October 23, 2019
Amazing kick off for #MassSTEMWeek at the WP! Thank you Mayor @marty_walsh, @VertexPharma CEO Jeff Leiden and Chief Scientist David Altshuler for visiting our Science classrooms. Shout out to Phil Thornton from @i2Learning for pulling it all together! #shapingyoungmindsforscience pic.twitter.com/ROXuDYHF6E
— Warren-Prescott K-8 (@Warren_Prescott) October 23, 2019
David Altshuler (@VertexPharma) kicks off #GA4GHPlenary2019 with remarks about how far the organization has come since its founding and how much is still yet to be done in #genomics and #datasharing pic.twitter.com/Ws77lE0wcG
— GA4GH (@GA4GH) October 21, 2019
"Every time I get a chance to interact with students like the ones from Prospect Hill Academy, it just blows me away."
-Jeffrey Leiden, CEO of @VertexPharma #MassSTEMWeek #seeyourselfinSTEM pic.twitter.com/38OqTRuOuj— ProspectHillAcademy (@PHACharter) October 21, 2019
We’re approaching the deadline to #registertovote, take a moment to check your voter registration status or register at https://t.co/RYkh4HRiMu #VoteReady
— Vertex (@VertexPharma) September 30, 2020
Vertex and The Vertex Foundation commit to supporting racial equity and social justice. Learn more: https://t.co/eexWQweo3g pic.twitter.com/nDGKZ9QrKo
— Vertex (@VertexPharma) June 25, 2020
Food banks across Germany have been severely impacted by #COVID19. In response, the Vertex Foundation announced a donation to #TAFEL to support their #COVID19 response fund. Learn more: https://t.co/c5gKTcspmt pic.twitter.com/fehqmtlRwo
— Vertex (@VertexPharma) June 16, 2020
The Vertex Foundation announces a donation to ARCAH to help with #COVID19 response efforts in São Paulo, Brazil. Learn more: https://t.co/VLtEaoMTOv pic.twitter.com/BpaH4XoLmR
— Vertex (@VertexPharma) June 16, 2020